Phase II · 2006
Pharmacokinetics, Pharmacodynamics, and Safety of CJC-1295 in Healthy Adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism
Single doses produced sustained 2–10x GH increases and 1.5–3x IGF-1 elevations lasting up to 6 days, establishing the long-acting profile.
Key findings
- Dose-dependent IGF-1 elevation
- No serious adverse events in the short observation window
- Half-life of roughly 6–8 days with the DAC modification
Limitations
Small Phase I/II cohort with short follow-up; no efficacy endpoints and no chronic-dosing safety data.